SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.

He added that a sudden, severe headache alongside double vision is another red flag. “Painful double vision, especially with ...

Experiencing double vision is often blamed on tiredness or stress - but it could signal that you're having a stroke, an eye ...

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

X recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered ...

Eye consultant Nadeem Ali says thousands of motorists could be unknowingly risking invalidating their insurance and getting ...

MotoGP’s Marc Márquez overcame 132 crashes and a laundry list of significant injuries to win a seventh world championship in 2025—but his focus is already on wh ...

Thousands of UK drivers could be unknowingly risking fines and invalidating their insurance, says eye surgeon Nadeem Ali ...

Argenx SE (NASDAQ: ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).

First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...